Windlas Biotech Limited — Credit Ratings, 08-04-2025: Credit Rating

Windlas Biotech Limited reported consolidated financial results reflecting a robust performance. Revenue for 9M FY2025 stood at ₹557.2 crore, achieving a year-over-year growth of approximately 21%. This growth can be attributed to increased demand in the contract development and manufacturing organization (CDMO) segment, along with expansion in the trade generics division, which has been bolstered by an expanding distribution network.

The net profit for the same period was ₹44.7 crore, with a profit margin of 8.0%. The profitability reflects stringent operational cost management, with operational costs slightly improving due to scale economies. The operational profit before depreciation, interest, taxes, and amortization (OPBDIT) margin is noted at 12.30%, suggesting effective cost control amid growing revenues.

The balance sheet remains favorable, supported by a strong liquidity position with cash and investments amounting to ₹181 crore. The total outside liabilities to tangible net worth ratio is low, indicating sustainable financial leverage and healthy coverage metrics.

Strategically, Windlas is focusing on expanding its capacity with the initiation of a new injectables facility, expected to begin operations by FY2026. This diversification into injectables is anticipated to enhance margins and revenue streams significantly. The current sentiment remains positive, suggesting buy or hold insights for retail investors as the company navigates its growth trajectory while managing operational risks effectively.